硒联合比索洛尔治疗自身免疫性甲状腺疾病(AITD)合并阵发性房颤临床疗效观察

Clinical efficacy observation of selenium and bisoprol therapy in patients with autoimmune thyroid diease(AITD) complicated by paroxysmal atrial fibrillation

目的本研究采用硒制剂联合比索洛尔治疗42例自身免疫性甲状腺疾病合并阵发性房颤的患者。方法应用电化学发光免疫法对所有患者均进行FT3、FT4、TSH含量检测以及甲状腺球蛋白抗体(TGAb)和甲状腺过氧化物酶抗体(TPOAb)测定。应用24 h动态心电图检测进行心功能评价。结果经过6个月联合治疗后,患者血清中FT3、FT4与治疗前相比无明显差异,TSH则明显上升。TGAb和TPOAb则较治疗前明显下降。患者心率较治疗前明显下降,75%患者房颤纠正。心脏左心室舒张功能明显改善。结论硒制剂联合比索洛尔对于自身免疫性甲状腺疾病合并阵发性房颤有治疗作用。

Objective The current study was designed to demonstrate the clinical efficacy observation of selenium and bisoprol therapy in 42 patients with autoimmune thyroid diease （AITD） complicated by paroxys- mal atrial fibrillation. Methods The levels of FT3 ,FF4 ,TSH.TGAb and TPOAb were determined by electro- chemiluminescence immunoassay. 24-hour dynamic electrocardiograms were applied to measure the function of heart. Results The levels of FT3 ,Fl＇4 were no different from without therapy after 6 months of application of selenium and bisoprol. But the levels of TSH were increased significantly, while TGAb and TPOAb decreased significantly. The heart rates of patients decreased significantly, in 75 percent of the patients with atrial fibrilla- tion were corrected. The Left ventricular diastolic function of heart reformed obviously. Conclusion Results of our study indicate that selenium and bisoprol therapy in patients with autoimmune thyroid diease complicated by paroxysmal atrial fibrillation was valid.